Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Rhythm Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Rhythm Pharmaceuticals, Inc.’s stock price such as:

• Rhythm Pharmaceuticals, Inc.’s current stock price and volume
• Why Rhythm Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for RYTM from analysts
• RYTM’s stock price momentum as measured by its relative strength

About Rhythm Pharmaceuticals, Inc. (RYTM)

Before we jump into Rhythm Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Want to learn more about Rhythm Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Rhythm Pharmaceuticals, Inc..

Rhythm Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of August 07, 2026, 2:00 PM, CST, Rhythm Pharmaceuticals, Inc.’s stock price was $114.965.

Rhythm Pharmaceuticals, Inc. is up 2.56% from its previous closing price of $112.100.

During the last market session, Rhythm Pharmaceuticals, Inc.’s stock traded between $111.690 and $116.130. Currently, there are approximately 68.59 million shares outstanding for Rhythm Pharmaceuticals, Inc..

Rhythm Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Rhythm Pharmaceuticals, Inc. Stock Price History

Rhythm Pharmaceuticals, Inc.’s (RYTM) price is currently up 15.83% so far this month.

During the month of August, Rhythm Pharmaceuticals, Inc.’s stock price has reached a high of $116.130 and a low of $97.565.

Over the last year, Rhythm Pharmaceuticals, Inc. has hit prices as high as $122.200 and as low as $74.500. Year to date, Rhythm Pharmaceuticals, Inc.’s stock is up 7.4%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Rhythm Pharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 06, 2026, there were 0 analysts who downgraded Rhythm Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Rhythm Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Rhythm Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Rhythm Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Rhythm Pharmaceuticals, Inc. (RYTM) by visiting AAII Stock Evaluator.

Relative Price Strength of Rhythm Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 06, 2026, Rhythm Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 3.10%, which translates to a Momentum Score of 65 and is considered to be Strong.

Want to learn more about how Rhythm Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Rhythm Pharmaceuticals, Inc. Stock Price: Bottom Line

As of August 7, 2026, Rhythm Pharmaceuticals, Inc.’s stock price is $114.965, which is up 2.56% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Rhythm Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.